MCID: ORP003
MIFTS: 50

Oropharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Oropharynx Cancer

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer 11 14 16
Oropharyngeal Cancer 11 53 14 75
Malignant Neoplasm of Oropharynx 71 31
Oropharyngeal Carcinoma 11 71
Malignant Tumour of Mesopharynx 11
Malignant Oropharyngeal Tumor 11
Malignant Tumor of Oropharynx 11
Oropharyngeal Cancer, Adult 19
Cancer of the Oropharynx 19

Classifications:



External Ids:

Disease Ontology 11 DOID:8557
NCIt 49 C7398
UMLS 71 C0153382 C0153388 C0153389 more

Summaries for Oropharynx Cancer

GARD: 19 A primary or metastatic malignant neoplasm that affects the oropharynx.

MalaCards based summary: Oropharynx Cancer, also known as oropharyngeal cancer, is related to papilloma and laryngeal benign neoplasm. An important gene associated with Oropharynx Cancer is ADH1C (Alcohol Dehydrogenase 1C (Class I), Gamma Polypeptide), and among its related pathways/superpathways are Endometrial cancer and Malignant pleural mesothelioma. The drugs Mitomycin and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include the, tonsil and tongue, and related phenotype is integument.

Disease Ontology: 11 A pharynx cancer that is located in the oropharynx.

Wikipedia: 75 Oropharyngeal cancer (OPC), also known as oropharyngeal squamous cell carcinoma (OPSCC) and tonsil... more...

Related Diseases for Oropharynx Cancer

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 633)
# Related Disease Score Top Affiliating Genes
1 papilloma 31.1 TP53 ERBB2 EGFR CDKN2A
2 laryngeal benign neoplasm 31.0 TP53 EGFR CDKN2A
3 pharynx cancer 30.9 MIR99A MIR93 MIR486-1 MIR21 MIR196A1 H2AC18
4 cervical cancer 30.8 TP53 MIR93 MIR21 MIR196A1 ERBB2 CDKN2A
5 oral squamous cell carcinoma 30.7 MIR99A MIR93 MIR486-1 MIR21 MIR196A1 H2AC18
6 hypopharynx cancer 30.7 TP53 EGFR CDKN2A CD274
7 head and neck cancer 30.7 TP53 MIR99A MIR93 MIR486-1 MIR21 MIR196A1
8 alcohol use disorder 30.6 SERPINA3 MIR196A1 H2AC18 ADH1C
9 keratinizing squamous cell carcinoma 30.6 TP53 EGFR CDKN2A
10 tongue carcinoma 30.6 TP53 MIR99A MIR21 EGFR CDKN2A
11 lip and oral cavity cancer 30.6 TP53 MIR21 KIT EGFR CDKN2A ADH1C
12 squamous cell carcinoma, head and neck 30.6 TP53 MIR99A MIR486-1 MIR21 MIR196A1 MIR193B
13 viral infectious disease 30.5 SERPINA3 MIR21 H2AC18 CD274
14 anogenital venereal wart 30.5 TP53 H2AC18 GP5 CDKN2A
15 anus cancer 30.5 TP53 H2AC18 GP5 ERBB2 EGFR CDKN2A
16 atypical teratoid rhabdoid tumor 30.3 TP53 H2AC18 EGFR CDKN2A
17 penile benign neoplasm 30.3 TP53 GP5 CDKN2A CD274
18 sweat gland cancer 30.3 TP53 MAML2 KIT ERBB2
19 skin squamous cell carcinoma 30.3 TP53 MIR21 ERBB2 EGFR CDKN2A
20 tonsil cancer 30.3 TP53 SERPINA3 NFIB MYBL1 MIR93 MIR193B
21 small cell cancer of the lung 30.3 TP53 MIR21 KIT EGFR CDKN2A
22 tonsil squamous cell carcinoma 30.3 MIR193B CDKN2A
23 adenocarcinoma 30.3 TP53 ERBB2 EGFR CDKN2A CD274
24 larynx cancer 30.3 TP53 MIR93 MIR486-1 MIR21 MIR196A1 EGFR
25 penile cancer 30.2 TP53 GP5 EGFR CDKN2A CD274
26 tongue squamous cell carcinoma 30.2 TP53 MIR99A MIR486-1 MIR21 MIR196A1
27 exanthem 30.2 KIT H2AC18 ERBB2 EGFR CD274
28 lymphatic system disease 30.2 TP53 SERPINA3 MIR93 MIR486-1 MIR21 MIR196A1
29 oral cavity cancer 30.2 MIR99A MIR93 MIR486-1 MIR21 MIR196A1 MIR193B
30 deficiency anemia 30.1 TP53 SERPINA3 MIR486-1 KIT H2AC18
31 interstitial lung disease 2 30.1 TP53 SERPINA3 MIR486-1 MIR21 MIR196A1 H2AC18
32 suppression of tumorigenicity 12 30.1 TP53 SERPINA3 H2AC18 ERBB2 EGFR CDKN2A
33 ovarian disease 30.1 TP53 MIR93 MIR486-1 MIR21 MIR193B H2AC18
34 meningioma, familial 30.1 TP53 SERPINA3 KIT H2AC18 ERBB2 EGFR
35 adenoid cystic carcinoma 30.1 TP53 SERPINA3 NFIB MYBL1 KIT ERBB2
36 esophageal cancer 30.1 TP53 MIR99A MIR93 MIR486-1 MIR21 MIR196A1
37 human papillomavirus infectious disease 30.1 TP53 MIR486-1 MIR21 MIR196A1 MIR193B GP5
38 tongue disease 30.0 TP53 MIR99A MIR486-1 MIR21 MIR196A1 MIR193B
39 myelodysplastic syndrome 30.0 TP53 KIT H2AC18 ERBB2 CDKN2A
40 nasopharyngeal carcinoma 30.0 TP53 MIR99A MIR93 MIR486-1 MIR21 MIR196A1
41 skin carcinoma 30.0 TP53 MIR21 KIT H2AC18 ERBB2 EGFR
42 lung squamous cell carcinoma 30.0 TP53 MIR93 MIR196A1 MIR193B H2AC18 EGFR
43 lung cancer susceptibility 3 30.0 TP53 MIR93 MIR486-1 MIR21 MIR196A1 H2AC18
44 ovarian cancer 29.8 TP53 MIR99A MIR21 MIR196A1 KIT H2AC18
45 peripheral nervous system disease 29.8 TP53 SERPINA3 MIR486-1 MIR21 MIR196A1 KIT
46 leukemia, acute myeloid 29.6 TP53 SERPINA3 MIR93 MIR486-1 MIR21 MIR196A1
47 breast cancer 29.6 TP53 SERPINA3 MIR93 MIR486-1 MIR21 MIR196A1
48 connective tissue disease 29.6 TP53 SERPINA3 MIR99A MIR93 MIR486-1 MIR21
49 lung cancer 29.6 TP53 SERPINA3 MIR99A MIR93 MIR486-1 MIR21
50 cutaneous telangiectasia and cancer syndrome, familial 11.6

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:



Diseases related to Oropharynx Cancer

Symptoms & Phenotypes for Oropharynx Cancer

MGI Mouse Phenotypes related to Oropharynx Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.28 CD274 CDKN2A EGFR ERBB2 KIT MIR193B

Drugs & Therapeutics for Oropharynx Cancer

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 150)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitomycin Approved Phase 4 50-07-7 5746
2
Cisplatin Approved Phase 3 15663-27-1 2767 5702198 441203
3
Fluorouracil Approved Phase 3 51-21-8 3385
4
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
5
Clonidine Approved Phase 2, Phase 3 4205-91-8, 4205-90-7 2803 20179
6
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
7
Sucralfate Approved Phase 3 54182-58-0
8
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3 135329020
9
Carboplatin Approved Phase 3 41575-94-4 10339178 38904
10
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3 3680
11
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 3003 5743
12
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
13
Cetuximab Approved Phase 3 205923-56-4
14
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
15 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
16 Immunosuppressive Agents Phase 3
17 Antimetabolites Phase 3
18 Anti-Anxiety Agents Phase 3
19 Excitatory Amino Acid Antagonists Phase 3
20 Psychotropic Drugs Phase 3
21 Anticonvulsants Phase 3
22 Neurotransmitter Agents Phase 2, Phase 3
23 Anti-Ulcer Agents Phase 3
24 Antacids Phase 3
25 Gastrointestinal Agents Phase 3
26 Mitogens Phase 2, Phase 3
27 Adrenergic alpha-Agonists Phase 2, Phase 3
28 Adrenergic Agonists Phase 2, Phase 3
29 Adrenergic Agents Phase 2, Phase 3
30 Antihypertensive Agents Phase 2, Phase 3
31 Analgesics Phase 2, Phase 3
32 Sympatholytics Phase 2, Phase 3
33 Aloe Phase 3
34 Angiogenesis Inhibitors Phase 2, Phase 3
35 Endothelial Growth Factors Phase 2, Phase 3
36 Immunologic Factors Phase 2, Phase 3
37 Antineoplastic Agents, Hormonal Phase 3
38 Hormones Phase 3
39 Antimitotic Agents Phase 3
40 Hormone Antagonists Phase 3
41 Antiemetics Phase 3
42 Tubulin Modulators Phase 3
43 glucocorticoids Phase 3
44 Anti-Inflammatory Agents Phase 3
45 Antineoplastic Agents, Immunological Phase 2, Phase 3
46 Immunoglobulins Phase 2, Phase 3
47 Antibodies Phase 2, Phase 3
48 Antibodies, Monoclonal Phase 2, Phase 3
49 HIV Protease Inhibitors Phase 3
50 BB 1101 Phase 3

Interventional clinical trials:

(show top 50) (show all 223)
# Name Status NCT ID Phase Drugs
1 Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer Active, not recruiting NCT03691441 Phase 4 Chemotherapy
2 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
3 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Completed NCT00964977 Phase 3
4 Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia Completed NCT01874587 Phase 3
5 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
6 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed NCT00158678 Phase 3 concomitant cisplatin
7 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
8 Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma Completed NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
9 Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx Completed NCT00003627 Phase 3 cisplatin;fluorouracil
10 Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck Recruiting NCT01893307 Phase 2, Phase 3
11 A Phase 2b/3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Clonidine Mucoadhesive Buccal Tablet to Placebo to Prevent Chemoradiotherapy-induced Severe Oral Mucositis in Patients With Oropharyngeal Cancer Recruiting NCT04648020 Phase 2, Phase 3 Clonidine HCl Mucoadhesive Buccal Tablet;Placebo Mucoadhesive Buccal Tablet
12 Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer Recruiting NCT04116047 Phase 3 Cisplatin;Durvalumab
13 Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy Recruiting NCT04019548 Phase 3 Cisplatin injection
14 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Recruiting NCT03952585 Phase 2, Phase 3 Cisplatin
15 A Phase III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer Recruiting NCT02215265 Phase 3 Cisplatin
16 Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis: a Single-blind Randomized Controlled Trial Recruiting NCT05369234 Phase 3 Carafate
17 A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC Recruiting NCT03811015 Phase 2, Phase 3 Cisplatin
18 A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Recruiting NCT05063552 Phase 2, Phase 3 Carboplatin;Cisplatin;Docetaxel
19 An Investigation of Postoperative Pain, Why Still in Hospital and Days Alive and Out of Hospital Following Transoral Robotic Surgery for Squamous Cell Carcinoma of Unknown Primary and Obstructive Sleep Apnea Active, not recruiting NCT04189107 Phase 3 Dexamethasone;Placebo
20 The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer Active, not recruiting NCT01706939 Phase 3 Carboplatin
21 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer Active, not recruiting NCT01302834 Phase 3 cisplatin
22 DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer Active, not recruiting NCT02908477 Phase 3 Docetaxel;Cisplatin
23 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Active, not recruiting NCT03258554 Phase 2, Phase 3
24 Primary Surgery Vs Primary Chemoradiation for Oropharyngeal Cancer (Scope Trial) - A Phase II/III Integrated Design Randomized Control Trial Not yet recruiting NCT05144100 Phase 2, Phase 3 Cisplatin based chemotherpay
25 SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer. A Phase III Randomized Controlled Trial Not yet recruiting NCT05451004 Phase 3
26 Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) Terminated NCT00537199 Phase 3 OraTest
27 Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer Terminated NCT01066741 Phase 3 Homeodent®;1.4% Sodium Bicarbonate solution
28 Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
29 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
30 Phase II Evaluation of Adjuvant Hyperfractionated Radiation and Docetaxel for HPV Associated Oropharynx Cancer Unknown status NCT01932697 Phase 2 Docetaxel
31 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
32 Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer Completed NCT00006360 Phase 1, Phase 2 radioprotection
33 Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer Completed NCT01032928 Phase 2
34 Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer Completed NCT03258008 Phase 2 Utomilumab
35 Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01440270 Phase 2 Neo-adjuvant Erbitux-based chemotherapy
36 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer Completed NCT02159703 Phase 2
37 A Phase I/II Study of T Cell Receptor Gene Therapy Targeting HPV-16 E6 for HPV-Associated Cancers Completed NCT02280811 Phase 1, Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
38 Physiotherapy Versus no Physiotherapy to Patients Suffering From Head and Neck Cancer Undergoing Radiotherapy Treatment Completed NCT00780312 Phase 2
39 Efficacy Evaluation of the Combination of Valproic Acid and Standard Platinum-based Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Completed NCT01695122 Phase 2 Valproic Acid
40 Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy Completed NCT04251949 Phase 2
41 A Randomized, Phase II Study of Ficlatuzumab With or Without Cetuximab in Patients With Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Completed NCT03422536 Phase 2 Ficlatuzumab
42 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
43 Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial) Completed NCT01733797 Phase 2
44 A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Aldesleukin for Human Papillomavirus-Associated Cancers Completed NCT01585428 Phase 2 Fludarabine;Cyclophosphamide;Aldesleukin
45 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
46 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
47 A Phase II, Randomized, Open-Label, Single Center Study In Patients With Advanced Head And Neck Cancer To Investigate Efficacy And Safety Of Standard Chemoradiation And Add-On Concurrent Cetuximab ± Consolidation Cetuximab Completed NCT01435252 Phase 2 Cetuximab
48 Minocycline for Reduction of Radiation Therapy Treatment-Related Symptom Burden in Oropharynx Cancer: A Randomized Study. Completed NCT01173692 Phase 2 Minocycline;Placebo
49 A Prospective Non-Inferiority Trial of the Use of Adaptive Radiotherapy for Head and Neck Cancer Undergoing Radiation Therapy Completed NCT03096808 Phase 2
50 Phase I/II Study of Split-dose TPF-Induction Chemotherapy Before Surgery of Oropharyngeal and Cavity of the Mouth Cancer Completed NCT01108042 Phase 1, Phase 2 Taxotere, Cisplatin, 5-Fluorouracil (5-FU)

Search NIH Clinical Center for Oropharynx Cancer

Genetic Tests for Oropharynx Cancer

Anatomical Context for Oropharynx Cancer

Organs/tissues related to Oropharynx Cancer:

FMA: The
MalaCards : Tonsil, Tongue, Lymph Node, T Cells, Colon, Endothelial, Salivary Gland

Publications for Oropharynx Cancer

Articles related to Oropharynx Cancer:

(show top 50) (show all 4604)
# Title Authors PMID Year
1
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. 53 62
17378915 2007
2
Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. 53 62
9050916 1997
3
Successful Hypoglossal Nerve Upper Airway Stimulator Implantation After Chemoradiotherapy for Oropharynx Malignancy Complicated by Mandibular Osteoradionecrosis. 62
33405965 2023
4
Thirteen cancers associated with HIV infection in a Black South African cancer patient population (1995-2016). 62
36054877 2023
5
Do Health-Seeking Populations Know the Link Between Human Papillomavirus and Oropharyngeal Cancer? A Cross-Sectional Study in a Nigerian Population. 62
33818212 2023
6
TORPEdO: A phase III trial of intensity-modulated proton beam therapy versus intensity-modulated radiotherapy for multi-toxicity reduction in oropharyngeal cancer. 62
36452431 2023
7
HPV impact on oropharyngeal cancer radiological staging: 7th vs 8th edition of AJCC TNM classification. 62
36375362 2023
8
External validation of a CT-based radiomics signature in oropharyngeal cancer: assessing sources of variation. 62
36464179 2022
9
An interpretable machine learning prognostic system for risk stratification in oropharyngeal cancer. 62
36279655 2022
10
Erratum to Studying prognostic significance of cytic nodal metastasis in HPV-positive oropharyngeal cancer. 62
36167479 2022
11
Investigation of the diversity of human papillomavirus 16 variants and L1 antigenic regions relevant for the prevention of human papillomavirus-related oropharyngeal cancer in Japan. 62
35491282 2022
12
Peeling Back the Curtain on Circulating HPV Tumor DNA as a Pretreatment Biomarker in Oropharyngeal Cancer. 62
36301555 2022
13
Association of Pretreatment Circulating Tumor Tissue-Modified Viral HPV DNA With Clinicopathologic Factors in HPV-Positive Oropharyngeal Cancer. 62
36301568 2022
14
External validation of an MR-based radiomic model predictive of locoregional control in oropharyngeal cancer. 62
36460924 2022
15
The psychosocial experiences of human papillomavirus (HPV) positive oropharyngeal cancer patients following (chemo)radiotherapy: A systematic review and meta-ethnography. 62
35726440 2022
16
Intraoperative Use of Wide-Field Optical Coherence Tomography to Evaluate Tissue Microstructure in the Oral Cavity and Oropharynx. 62
36454583 2022
17
Prevalence and risk factors of retro-styloid lymph node metastasis in oropharyngeal carcinoma. 62
35098812 2022
18
Prediction of extranodal extension in oropharyngeal cancer patients and carcinoma of unknown primary: value of metabolic tumor imaging with hybrid PET compared with MRI and CT. 62
36471046 2022
19
Correlation between radiologic and pathologic extranodal extension in HPV-associated oropharyngeal cancer: Systematic review. 62
36071683 2022
20
Low postoperative lymphocyte count increases risk of progression in human papillomavirus associated oropharyngeal cancer. 62
36129387 2022
21
Simultaneously Integrated Boost Affects Survival in Locally Advanced p16-Negative Oropharyngeal Squamous Cell Carcinoma. 62
36456162 2022
22
Volumetric staging in radiotherapy for oropharyngeal cancers. 62
34628998 2022
23
Geriatric Pharmacotherapy Case Series: Thiazide-Induced Hypokalemia. 62
36461138 2022
24
Stark differences in cancer epidemiological data between GLOBOCAN and GBD: Emphasis on oral cancer and wider implications. 62
36247925 2022
25
The College of American Pathologists Foundation's See, Test & Treat Program®: an Evaluation of a One-Day Cancer Screening Program Implemented in Mississippi. 62
34164764 2022
26
Surgical salvage of human papillomavirus-positive oropharyngeal cancer: Secondary analysis of a randomized controlled trial. 62
36401615 2022
27
Dynamic nomogram for long-term survival in patients with locally advanced oropharyngeal cancer after (chemo)radiotherapy. 62
36427081 2022
28
Raman spectroscopy in oral cavity and oropharyngeal cancer: a systematic review. 62
35282942 2022
29
Temporal trends in oropharyngeal cancer incidence, survival, and cancer-directed surgery among elderly Americans. 62
36191478 2022
30
Osteoradionecrosis rate in oropharynx cancer treated with dose volume histogram based constraints. 62
36252636 2022
31
Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. 62
36369568 2022
32
Near-Infrared Photoimmunotherapy for Oropharyngeal Cancer. 62
36428754 2022
33
Evaluation of Optimal Assessment Schedules for Surveillance After Definitive Locoregional Treatment of Locally Advanced Head and Neck Cancer: A Retrospective Cohort Study With Parametric Modeling of Event-Free Survival. 62
36173618 2022
34
Oncologic outcomes of salvage surgery and immune checkpoint inhibitor therapy in recurrent head and neck squamous cell carcinoma: A single-institution retrospective study. 62
35930296 2022
35
Prevalence of Human Papillomavirus and Co-Infection with Epstein-Barr Virus in Oral and Oropharyngeal Squamous Cell Carcinomas. 62
36444607 2022
36
Immunogenetic Determinants of Susceptibility to Head and Neck Cancer in the Million Veteran Program Cohort. 62
36378845 2022
37
Two-Year Tumor Outcomes of a Phase 2B, Randomized, Double-Blind Trial of Avasopasem Manganese (GC4419) Versus Placebo to Reduce Severe Oral Mucositis Owing to Concurrent Radiation Therapy and Cisplatin for Head and Neck Cancer. 62
35724774 2022
38
Spot scanning proton arc therapy reduces toxicity in oropharyngeal cancer patients. 62
36373893 2022
39
Toxicity Profiles and Survival Outcomes Among Patients With Nonmetastatic Oropharyngeal Carcinoma Treated With Intensity-Modulated Proton Therapy vs Intensity-Modulated Radiation Therapy. 62
36367724 2022
40
Novel Strategies for Managing Retropharyngeal Lymph Node Metastases in Head and Neck and Thyroid Cancer with Transoral Robotic Surgery (TORS). 62
35842533 2022
41
Correction: Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients. 62
36282237 2022
42
Immune-based classification of HPV-associated oropharyngeal cancer with implications for biomarker-driven treatment de-intensification. 62
36442320 2022
43
Impact of Alcohol and Smoking on Outcomes of HPV-Related Oropharyngeal Cancer. 62
36362736 2022
44
Absolute Risk of Oropharyngeal Cancer After an HPV16-E6 Serology Test and Potential Implications for Screening: Results From the Human Papillomavirus Cancer Cohort Consortium. 62
35700419 2022
45
DNA hypermethylation of CADM1, PAX5, WT1, RARβ, and PAX6 genes in oropharyngeal cancer associated with human papillomavirus. 62
34974810 2022
46
Oropharyngeal cancer associated with sarcopenic obesity and sarcopenic weight loss. 62
36058059 2022
47
Corrigendum to "Similar long-term swallowing outcomes for accelerated, mildly-hypofractionated radiotherapy compared to conventional fractionation in oropharynx cancer: A multi-centre study" [Radiother. Oncol. 172 (2022) 111-117]. 62
36395551 2022
48
The Current Burden of Oropharyngeal Cancer: A Global Assessment Based on GLOBOCAN 2020. 62
36173880 2022
49
Triple variation in the vascular supply in the neck of a female donor body: a case report. 62
36242606 2022
50
Oncogenic viruses as etiological risk factors for head and neck cancers: An overview on prevalence, mechanism of infection and clinical relevance. 62
36049431 2022

Variations for Oropharynx Cancer

Expression for Oropharynx Cancer

Search GEO for disease gene expression data for Oropharynx Cancer.

Pathways for Oropharynx Cancer

Pathways related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.34 TP53 KIT ERBB2 EGFR CDKN2A
2 12.27 TP53 KIT EGFR CDKN2A CD274
3
Show member pathways
12.19 TP53 KIT ERBB2 EGFR
4
Show member pathways
11.56 KIT ERBB2 EGFR
5 11.42 TP53 CRTC1 CDKN2A
6 11.37 TP53 MIR93 MIR21
7 11.32 TP53 ERBB2 EGFR CDKN2A
8 11.05 TP53 NFIB MYBL1 ERBB2
9 10.53 TP53 ERBB2 EGFR CDKN2A

GO Terms for Oropharynx Cancer

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of miRNA maturation GO:1903800 9.16 TP53 EGFR
2 negative regulation of immature T cell proliferation in thymus GO:0033088 9.13 ERBB2 CDKN2A
3 positive regulation of vascular associated smooth muscle cell differentiation GO:1905065 8.8 MIR21 KIT

Molecular functions related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.43 TP53 MIR93 MIR486-1 MIR21 MIR193B
2 mRNA base-pairing translational repressor activity GO:1903231 9.1 MIR99A MIR93 MIR486-1 MIR21 MIR196A1 MIR193B

Sources for Oropharynx Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....